Ginkgo bioworks and saponiqx awarded mcdc contract to discover and manufacture next-generation vaccine adjuvants using generative molecular design

Boston and lexington, mass. , feb. 15, 2024 /prnewswire/ -- the defense threat reduction agency's (dtra) joint science and technology office (jsto) for the chemical and biological defense (cbd) program has awarded, through the medical cbrn [chemical, biological, radiological, and nuclear] defense consortium (mcdc) requirement 22-05, "adjuvant activity to vaccines prototype," a 5-year contract totaling up to $31 million including program options to the team of ginkgo bioworks, inc. (nyse: dna) and saponiqx, inc. (a subsidiary of agenus inc., nasdaq:agen) to discover and develop next-generation vaccine adjuvants.
AGEN Ratings Summary
AGEN Quant Ranking